Irvine, CA, United States of America

Mei Peng

USPTO Granted Patents = 15 

Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2010-2022

Loading Chart...
15 patents (USPTO):Explore Patents

Title: Mei Peng: Innovator in Cystic Fibrosis Research

Introduction

Mei Peng is a prominent inventor based in Irvine, CA, who has made significant contributions to the field of genetics, particularly in relation to cystic fibrosis. With a total of 15 patents to his name, he has been at the forefront of research aimed at understanding and addressing genetic mutations associated with this condition.

Latest Patents

Among his latest patents, Mei Peng has developed innovative methods related to cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations. His inventions provide novel mutations of the CFTR gene that are linked to cystic fibrosis and other related conditions. Additionally, he has created probes for detecting these mutant sequences, along with methods for identifying individuals with genotypes containing one or more mutations in the CFTR gene.

Career Highlights

Mei Peng is currently associated with Quest Diagnostics Investments, Inc., where he continues to advance his research and innovations. His work has not only contributed to the scientific community but has also paved the way for potential therapeutic applications in treating cystic fibrosis.

Collaborations

Throughout his career, Mei has collaborated with notable colleagues, including Matthew J McGinniss and Arlene M Buller, who have supported his research endeavors and contributed to the development of his patents.

Conclusion

Mei Peng's work in the field of cystic fibrosis research exemplifies the impact of innovation in genetics. His patents and ongoing research efforts are crucial in the fight against this challenging condition, highlighting the importance of continued exploration and discovery in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…